Delayed Research on DCA
Scientists and researchers believe lack of proper funding led to delay in studying DCA’s effect on cancer. They also believe the inability to patent DCA, has discouraged the pharmaceutical companies to fund the research. Dr. Evangelos Michelakis was quoted saying:
“Big Pharma has no interest whatsoever in investing [in DCA research] because there will be no profit.”
Dr. Michelakis team is currently working on phase three clinical trials. Individuals and philanthropic groups are funding the study privately.
DCA has not been tested on humans in the USA, and its research is not yet finalized in Canada. Public funds have in fact helped the research team at the University of Alberta to complete their phase two clinical studies. Hopefully, Dr. Michelakis’s clinical trials of DCA will be successful and we get to hear a positive news.
Consequently, a clinical trial of DCA for a childhood disease resulted in significant side effects, affecting the nervous system.
Since DCA is still under test in the lab, it’s better cancer patients do not take it. On the other hand, researchers have also found that DCA can cause cancer in animals. It is also an environmental pollutant.
Hoax or Fact:
Small molecule DCA offers hope for cancer treatment
Canadian study – DCA Inhibits Cancer Growth – Cancer Cell journal
Potential cancer drug DCA tested in early trials
Big Pharma Ignoring a Potential Cancer Cure?